BioCryst Pharmaceuticals | BCRX - Net Income


BioCryst Pharmaceuticals reported $78.4M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Chugai Pharma JPY 116.33B 913M Jun/2026
Daiichi Sankyo JPY 68.64B 18B Jun/2026
DBV Technologies USD -47.6M 2.77M Mar/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Glaxosmithkline GBP 1.74B 890.94M Mar/2026
Incyte USD 585.6M 282.27M Jun/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Novavax USD 17.53M 219.91M Dec/2025
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026